Introduction
The first gene therapy trial in humans aimed to correct adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID).
1 Since that time this approach has been Hematopoietic stem cell transplantation (HCT) is incorporated into therapy of both hematologic malignancies and solid tumors. the T cell approach, the need for further control arises with transduction of HSCs due to the potential for insertional oncogenesis. 6-9 Here we will comment on the use of TCRs and CARs in HSCs, as well as the feasible control by a suicide gene.
T Cell Receptors in HSCs
The clinical success of lymphocyte expressing exogenous TCR directed against NY- 
Chimeric Antigen Receptors into HSCs
Compared with TCRs, modification of HSCs with CAR brings the added advantage of a multi-lineage immunotherapy that is not HLA restricted. The vast majority of experience lies in the expression of CAR-modified T cells, but the efficacy of CAR expression on NK and myeloid cells has been demonstrated. [16] [17] [18] [19] Following HCT, the first cells to recover consist of myeloid cells followed by NK cells, which would result in an earlier anti-cancer therapy until de novo thymopoiesis. The theoretical benefits of modification of HSCs rather than T cells with CAR are described in Table 2 .
Early studies with first-generation CARs showed minimal success. The necessity of costimulation for effective T cell response is well described and likely explains the limited efficacy of the early attempts at CAR therapy using first-generation constructs containing the CD3ζ signaling domain alone. 20, 21 The constructs currently in use are mostly second-generation constructs that incorporate the CD28 or 4-1BB co-stimulatory domains, with each bringing a potential advantage. Third-generation CARs containing two of the domains (CD28, 4-1BB, OX-40) have also been developed, but there is concern that the increased number of co-stimulatory domains may escalate toxicity. The most studied CD28 and 4-1BB domains have yielded successful early results in clinical trials, with persistence of gene-modified cells being a relevant issue. 4, 22, 23 We have demonstrated that first and second-generation anti-CD19 CARs can effectively transduce HSCs and lead to CAR expression on myeloid, T cells, and NK cells. In our work, the transduction efficiency of human umbilical cord blood CD34+ cells is consistently between 40-50%. 24, 25 The gene-modified HSCs were then transplanted into irradiated NSG mice, which were subsequently harvested to evaluate for the presence and function of CAR. The CAR expressing cells were detected in the bone marrow, spleen, and peripheral blood, and the presence of CAR did not affect the ability of the cells to differentiate or to maintain effective cytotoxicity. Further, the presence of the CAR induced B cell aplasia serving as a surrogate of CAR activity. Engrafted mice presented significant protection against CD19-positive tumors, with inhibition or elimination of tumor development and consequent survival advantage.
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Suicide Gene Therapy
Addition of a suicide gene, a gene activated upon administration of a prodrug, to the modification of HSCs for gene therapy allows increased safety as concern for insertional oncogenesis exists. In the trials using LTR regulated gamma retrovirus to correct X-linked SCID, four patients developed acute leukemia. 6 Further, patients treated with CAR T cells have shown increased inflammatory responses that resemble sepsis, which has been termed cytokine release syndrome. [2] [3] [4] 22, 23 The nonrandom vector integration patterns and immune stimulation potential highlight the need for control of the gene-modified cells, which can be achieved through the addition of a suicide gene to the CAR vector. The currently used suicide genes include HSV-TK, icaspase 9, CD20, and a truncated epidermal growth factor receptor (EGFRt). 26-29 Table 3 provides an overview of some of the currently available suicide genes.
The most extensive experience exists with the HSV-TK gene in order to eliminate graft- 
Conclusions and Perspectives
The incorporation of gene transfer into cancer immunotherapy is creating promising new 
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